Charles River Laboratories International Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名5/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價189.43。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Charles River Laboratories International Inc評分
相關信息
行業排名
5 / 404
全市場排名
48 / 4592
所屬行業
生物技術與醫療研究
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
18
分析師
買入
評級
189.428
目標均價
+1.23%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Charles River Laboratories International Inc亮點
亮點風險
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
公司代碼CRL
公司Charles River Laboratories International Inc
CEOFoster (James C)
網址https://www.criver.com/
常見問題
Charles River Laboratories International Inc(CRL)的當前股價是多少?
Charles River Laboratories International Inc(CRL)的當前股價是 198.150。
Charles River Laboratories International Inc 的股票代碼是什麼?
Charles River Laboratories International Inc的股票代碼是CRL。
Charles River Laboratories International Inc股票的52週最高點是多少?
Charles River Laboratories International Inc股票的52週最高點是199.660。
Charles River Laboratories International Inc股票的52週最低點是多少?
Charles River Laboratories International Inc股票的52週最低點是91.861。
Charles River Laboratories International Inc的市值是多少?
Charles River Laboratories International Inc的市值是9.75B。
Charles River Laboratories International Inc的淨利潤是多少?
Charles River Laboratories International Inc的淨利潤為10.30M。
現在Charles River Laboratories International Inc(CRL)的股票是買入、持有還是賣出?
根據分析師評級,Charles River Laboratories International Inc(CRL)的總體評級為買入,目標價格為189.428。
Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是多少
Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是-1.530。